157 related articles for article (PubMed ID: 22539036)
1. AKR1B10 overexpression in breast cancer: association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Ma J; Luo DX; Huang C; Shen Y; Bu Y; Markwell S; Gao J; Liu J; Zu X; Cao Z; Gao Z; Lu F; Liao DF; Cao D
Int J Cancer; 2012 Sep; 131(6):E862-71. PubMed ID: 22539036
[TBL] [Abstract][Full Text] [Related]
2. AKR1B10 promotes breast cancer metastasis through integrin α5/δ-catenin mediated FAK/Src/Rac1 signaling pathway.
Huang C; Verhulst S; Shen Y; Bu Y; Cao Y; He Y; Wang Y; Huang D; Cai C; Rao K; Liao DF; Jin J; Cao D
Oncotarget; 2016 Jul; 7(28):43779-43791. PubMed ID: 27248472
[TBL] [Abstract][Full Text] [Related]
3. AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling.
Li J; Guo Y; Duan L; Hu X; Zhang X; Hu J; Huang L; He R; Hu Z; Luo W; Tan T; Huang R; Liao D; Zhu YS; Luo DX
Oncotarget; 2017 May; 8(20):33694-33703. PubMed ID: 28402270
[TBL] [Abstract][Full Text] [Related]
4. Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma.
Xie C; Ye X; Zeng L; Zeng X; Cao D
J Gastroenterol; 2023 Oct; 58(10):1030-1042. PubMed ID: 37500927
[TBL] [Abstract][Full Text] [Related]
5. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Ma J; Yan R; Zu X; Cheng JM; Rao K; Liao DF; Cao D
J Biol Chem; 2008 Feb; 283(6):3418-3423. PubMed ID: 18056116
[TBL] [Abstract][Full Text] [Related]
6. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
Ha SY; Song DH; Lee JJ; Lee HW; Cho SY; Park CK
Gut Liver; 2014 Nov; 8(6):648-54. PubMed ID: 25287169
[TBL] [Abstract][Full Text] [Related]
7. Statil suppresses cancer cell growth and proliferation by the inhibition of tumor marker AKR1B10.
Cao Z; Zhou B; Chen X; Huang D; Zhang X; Wang Z; Huang H; Wang Y; Cao D
Anticancer Drugs; 2014 Sep; 25(8):930-7. PubMed ID: 24800887
[TBL] [Abstract][Full Text] [Related]
8. AKR1B10, a good prognostic indicator in gastric cancer.
Yao HB; Xu Y; Chen LG; Guan TP; Ma YY; He XJ; Xia YJ; Tao HQ; Shao QS
Eur J Surg Oncol; 2014 Mar; 40(3):318-24. PubMed ID: 24406159
[TBL] [Abstract][Full Text] [Related]
9. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Ohashi T; Idogawa M; Sasaki Y; Suzuki H; Tokino T
Mol Cancer Res; 2013 Dec; 11(12):1554-63. PubMed ID: 24140838
[TBL] [Abstract][Full Text] [Related]
10. AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.
Huang C; Cao Z; Ma J; Shen Y; Bu Y; Khoshaba R; Shi G; Huang D; Liao DF; Ji H; Jin J; Cao D
Mol Carcinog; 2018 Oct; 57(10):1300-1310. PubMed ID: 29846015
[TBL] [Abstract][Full Text] [Related]
11. [Expression of aldo-keto reductase family 1 member B10 in gastric cancer tissues and its clinical significance].
Yao HB; Xu Y; Chen LG; Guan TP; Ma YY; Tao HQ; Shao QS
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Feb; 16(2):183-7. PubMed ID: 23446484
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
He YC; Shen Y; Cao Y; Tang FQ; Tian DF; Huang CF; Tao H; Zhou FL; Zhang B; Song L; He L; Lin LM; Lu FG; Liao DF; Cao D
Cancer Biomark; 2016; 16(1):127-35. PubMed ID: 26835713
[TBL] [Abstract][Full Text] [Related]
13. Aldo-keto reductase 1B10 as a Carcinogenic but Not a Prognostic Factor in Colorectal Cancer.
Ye X; Wang T; Zhong L; Farrés J; Xia J; Zeng X; Cao D
J Cancer; 2024; 15(6):1657-1667. PubMed ID: 38370384
[TBL] [Abstract][Full Text] [Related]
14. Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Chung YT; Matkowskyj KA; Li H; Bai H; Zhang W; Tsao MS; Liao J; Yang GY
Mod Pathol; 2012 May; 25(5):758-66. PubMed ID: 22222635
[TBL] [Abstract][Full Text] [Related]
15. AKR1B10 as a Potential Novel Serum Biomarker for Breast Cancer: A Pilot Study.
Cao Z; Delfino K; Tiwari V; Wang X; Hannan A; Zaidi F; McClintock A; Robinson K; Zhu Y; Gao J; Cao D; Rao K
Front Oncol; 2022; 12():727505. PubMed ID: 35280770
[TBL] [Abstract][Full Text] [Related]
16. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer.
Nakamura Y; Yasuoka H; Tsujimoto M; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
Breast Cancer Res Treat; 2005 May; 91(2):125-32. PubMed ID: 15868440
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
18. Aldo-keto reductase family 1, member B10 is secreted through a lysosome-mediated non-classical pathway.
Luo DX; Huang MC; Ma J; Gao Z; Liao DF; Cao D
Biochem J; 2011 Aug; 438(1):71-80. PubMed ID: 21585341
[TBL] [Abstract][Full Text] [Related]
19. Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
Morikawa Y; Kezuka C; Endo S; Ikari A; Soda M; Yamamura K; Toyooka N; El-Kabbani O; Hara A; Matsunaga T
Chem Biol Interact; 2015 Mar; 230():30-9. PubMed ID: 25686905
[TBL] [Abstract][Full Text] [Related]
20. The expression and significance of AKR1B10 in laryngeal squamous cell carcinoma.
Liu J; Ban H; Liu Y; Ni J
Sci Rep; 2021 Sep; 11(1):18228. PubMed ID: 34521883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
